The Gross Law Firm Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline

Core Viewpoint - The Gross Law Firm is notifying shareholders of Novo Nordisk A/S regarding a class action lawsuit due to alleged misleading statements about the company's growth potential and subsequent stock price decline [1][3]. Summary by Sections Allegations - The complaint alleges that Novo Nordisk provided overly positive statements while concealing material adverse facts about its growth potential, particularly regarding the compounded GLP-1 market and the likelihood of patients switching to its branded alternatives [3]. - On July 29, 2025, Novo announced a reduction in its sales and profit outlook for the second half of 2025, attributing this to lower growth expectations for its products Wegovy and Ozempic, compounded GLP-1 usage, slower market expansion, and competition [3]. - Following this announcement, Novo's stock price fell from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025, marking a decline of approximately 21.83% in one day [3]. Class Action Details - The class period for the lawsuit is from May 7, 2025, to July 28, 2025, and shareholders are encouraged to register for participation [3][4]. - The deadline for shareholders to seek lead plaintiff status is September 30, 2025, and there is no cost or obligation to participate in the case [4]. Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [5].